Spanish company buys out Peninsula ‘young blood’ company for $146M

A Spanish health care company at the forefront of turning plasma against Covid-19 will buy out a Stanford University spinout focused on age-defying proteins from the clear, yellowish liquid portion of blood. Grifols S.A. (NASDAQ: GRFS) said it will buy the rest of Alkahest Inc. that it didn't already own for $146 million. The deal is expected to close in early 2021. Grifols this summer started clinical trials of a potential Covid therapy made from hyperimmune globulin, preparations that are rich…

Click to view original post